Oxford Science Park based Nucleome is harnessing its ability to read the "dark genome" to develop therapies for inflammatory disease and beyond

blonca9
Sep 17, 2024
1 min read

Updated: Sep 18, 2024

New CEO Mark Bodmer describes the value in understanding the non-coding region of the genome and how he thinks Nucleome is in a unique position to put it into practice.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Oxford Science Park based Nucleome is harnessing its ability to read the "dark genome" to develop therapies for inflammatory disease and beyond

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight